Apellis Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for APELLIS PHARMS, and when can generic versions of APELLIS PHARMS drugs launch?
APELLIS PHARMS has two approved drugs.
There are thirteen US patents protecting APELLIS PHARMS drugs.
There are one hundred and seventy-three patent family members on APELLIS PHARMS drugs in twenty-six countries and twelve supplementary protection certificates in eleven countries.
Summary for Apellis Pharms
| International Patents: | 173 |
| US Patents: | 13 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Apellis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | 7,989,589 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | 11,040,107 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | 7,888,323 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | 11,292,815 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Apellis Pharms Drugs
Supplementary Protection Certificates for Apellis Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3660033 | CR 2022 00023 | Denmark | ⤷ Sign Up | PRODUCT NAME: PEGCETACOPLAN; REG. NO/DATE: EU/1/21/1595 20211214 |
| 3660033 | 2022C/522 | Belgium | ⤷ Sign Up | PRODUCT NAME: PEGCETACOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1595 20211214 |
| 3660033 | CA 2022 00023 | Denmark | ⤷ Sign Up | PRODUCT NAME: PEGCETACOPLAN; REG. NO/DATE: EU/1/21/1595 20211214 |
| 3660033 | C202230025 | Spain | ⤷ Sign Up | PRODUCT NAME: PEGCETACOPLAN; NATIONAL AUTHORISATION NUMBER: EU/1/21/1595; DATE OF AUTHORISATION: 20211213; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1595; DATE OF FIRST AUTHORISATION IN EEA: 20211213 |
| 3660033 | 2290021-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: PEGCETAKOPLAN; REG. NO/DATE: EU/1/21/1595 20211214 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
